Where Molecular Science
Meets Artificial Intelligence
Improving the Human Condition
Every human has a unique molecular code, one made up of a universe of biological networks that provide the source of life. And the root cause for nearly every type of disease is that an error has occurred somewhere in that code. At Caris Life Sciences, we’ve developed solutions and created innovative tools to analyze this biological web. These innovations hold the key to better detect, categorize, treat and inform, unraveling the molecular complexity of disease and helping improve patient outcomes.
Caris was founded in 2008 with a simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies informed by massive amounts of data, we are trailblazing the path to precision medicine by providing physicians and patients with the highest quality information about disease.
Products At-a-Glance
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous whole exome- and whole transcriptome-based assay with CDx indications for all solid tumors in adult and pediatric patients for therapy selection.
Caris Assure
Caris Assure® Therapy Selection is a novel blood-based WES/WTS assay that analyzes cfDNA and cfRNA from plasma, and genomic DNA and RNA from white blood cells.
AI Signatures
Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel solutions.
Changing Lives Through Precision Medicine
Our purpose is to help improve the lives of as many people as possible by transforming cancer care. Together, we move forward—with science, and with compassion, so that cancer patients can live longer.
Caris was built for one reason — to improve the human condition. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work — the patient.”
-David Dean Halbert, DSc (h.c.), Chairman, Founder and CEO
Driving Molecular Science Innovation
949,000+
Cases
6.5+ Million
Tests
50+ Billion
Molecular Markers Measured
With the molecular profiling done by Caris, my doctor was able to pinpoint treatment that would work best for my individual situation, which thankfully proved successful. Molecular profiling is so critical – information is such power.”
Patient, Diane Davis
Ovarian Cancer Survivor
Diane Davis, Ovarian Cancer Survivor
The Caris Continuum of Care
With products and services that support the full care continuum, we’re here for you every step of the way on your journey for the best possible outcome.
Disease Detection
Catch disease early when it can be more easily treated.
Therapy Selection
Inform therapy selection with molecular information about your specific cancer.
Treatment Monitoring
Monitor how your cancer is responding to treatment.